Ra Pharmaceuticals Inc (NASDAQ:RARX) saw a significant increase in short interest during the month of December. As of December 29th, there was short interest totalling 1,085,182 shares, an increase of 41.2% from the December 15th total of 768,462 shares. Based on an average trading volume of 175,349 shares, the short-interest ratio is currently 6.2 days. Currently, 11.7% of the shares of the stock are sold short.
A number of brokerages have weighed in on RARX. Zacks Investment Research raised shares of Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, September 26th. Jefferies Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Ra Pharmaceuticals in a research note on Thursday, September 28th. Credit Suisse Group boosted their target price on shares of Ra Pharmaceuticals from $19.00 to $23.00 and gave the stock an “outperform” rating in a research note on Friday, November 10th. BMO Capital Markets boosted their target price on shares of Ra Pharmaceuticals in a research note on Tuesday, December 5th. Finally, Royal Bank of Canada reaffirmed a “buy” rating and issued a $18.00 target price on shares of Ra Pharmaceuticals in a research note on Tuesday, December 5th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Ra Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $21.90.
Ra Pharmaceuticals (NASDAQ:RARX) opened at $8.49 on Friday. Ra Pharmaceuticals has a 12 month low of $7.15 and a 12 month high of $27.84. The firm has a market cap of $194.82, a PE ratio of -3.44 and a beta of 6.29.
Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.06). equities analysts predict that Ra Pharmaceuticals will post -2.46 EPS for the current fiscal year.
Several large investors have recently modified their holdings of RARX. Schwab Charles Investment Management Inc. grew its position in shares of Ra Pharmaceuticals by 70.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 21,800 shares of the company’s stock worth $409,000 after buying an additional 9,000 shares during the period. Rhumbline Advisers acquired a new stake in shares of Ra Pharmaceuticals during the 2nd quarter worth approximately $241,000. Bank of New York Mellon Corp grew its position in shares of Ra Pharmaceuticals by 57.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 37,932 shares of the company’s stock worth $711,000 after buying an additional 13,881 shares during the period. Swiss National Bank acquired a new stake in shares of Ra Pharmaceuticals during the 2nd quarter worth approximately $247,000. Finally, JPMorgan Chase & Co. grew its position in shares of Ra Pharmaceuticals by 33.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 199,900 shares of the company’s stock worth $3,746,000 after buying an additional 50,432 shares during the period. Institutional investors own 69.64% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/14/ra-pharmaceuticals-inc-rarx-short-interest-up-41-2-in-december.html.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.